Weiping Zou

Weiping Zou (Chinese: 邹伟平) is the Charles B. de Nancrede Professor of Pathology, Immunology, Biology, and Surgery at the University of Michigan. He is a scientist noted for his work regarding understanding the nature of human tumor immune responses and developing mechanism-informed combination therapies for cancer. He has developed an international reputation in human tumor immunosuppressive mechanisms in the tumor microenvironment.

Weiping Zou

MD, PhD
EmployerUniversity of Michigan
TitleCharles B. de Nancrede Professor
The native form of this personal name is Zou Weiping. This article uses Western name order when mentioning individuals.

Career

Zou serves as Director of the Center of Excellence for Cancer Immunology and Immunotherapy, Co-Director of the Cancer Hematopoiesis and Immunology Program, and directs the Immunologic Monitoring Core at the University of Michigan Medical School and Rogel Cancer Center. He also directs the Surgical Oncology Fellow Training (T32) program, through which clinical fellows are trained to become physician scientists, with a focus on cancer immunology and immunotherapy. At the national level, he is the American Association for Cancer Research Cancer Immunology (CIMM) Chairperson 2019-2020[1] and has served as the Abstract Programming Chair for the American Association of Immunologists in the last 4 years.

He has delivered more than 300 invited lectures at different institutions and conferences and has published more than 170 articles and book chapters including many articles in Nature, Science, and Cell journal series. His laboratory is one of the most cited research teams in the field of immunology and their work has been highlighted by many scientific news agencies. “Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival”,[2] an original work on human Tregs, has been cited more than 4,000 times since its publication.[2]

Recent Publications
  1. J Li, W Wang , Y Zhang , M Cieślik, J Guo J, M Tan, MD Green, W Wang, H Lin, W Li, S Wei, J Zhou, G Li, X Jing, L Vatan, L Zhao, B Bitler, R Zhang, KR Cho, Y Dou, I Kryczek, TA Chan, D Huntsman, AM Chinnaiyan, W Zou. Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy. J Clin Invest (2020).
  2. W. Zou, Y. M. Shah, A PHD in immunosuppression: oxygen-sensing pathways regulate immunosuppressive Tregs. J Clin Invest 130, 3524-3526 (2019).
  3. Q. Zhang, M. D. Green, X. Lang, J. Lazarus, J. D. Parsels, S. Wei, L. A. Parsels, J. Shi, N. Ramnath, D. R. Wahl, M. Pasca di Magliano, T. L. Frankel, I. Kryczek, Y. L. Lei, T. S. Lawrence, W. Zou, M. A. Morgan, Inhibition of ATM Increases Interferon Signaling and Sensitizes Pancreatic Cancer to Immune Checkpoint Blockade Therapy. Cancer Res 79, 3940-3951 (2019).
  4. C. Y. Yu, J. X. Han, J. Zhang, P. Jiang, C. Shen, F. Guo, J. Tang, T. Yan, X. Tian, X. Zhu, D. Ma, Y. Hu, Y. Xie, W. Du, M. Zhong, J. Chen, Q. Liu, D. Sun, Y. Chen, W. Zou, J. Hong, H. Chen, J. Y. Fang, A 16q22.1 variant confers susceptibility to colorectal cancer as a distal regulator of ZFP90. Oncogene, (2019).
  5. W. Wang, J. R. Liu, W. Zou, Immunotherapy in Ovarian Cancer. Surg Oncol Clin N Am 28, 447-464 (2019).
  6. W. Wang, M. Green, J. E. Choi, M. Gijon, P. D. Kennedy, J. K. Johnson, P. Liao, X. Lang, I. Kryczek, A. Sell, H. Xia, J. Zhou, G. Li, J. Li, W. Li, S. Wei, L. Vatan, H. Zhang, W. Szeliga, W. Gu, R. Liu, T. S. Lawrence, C. Lamb, Y. Tanno, M. Cieslik, E. Stone, G. Georgiou, T. A. Chan, A. Chinnaiyan, W. Zou, CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature 569, 270-274 (2019).
  7. Zhong, J. Chen, Z. Ge, X. Li, X. Chen, Y. Cui, Y. Chen, W. Zou, H. Chen, J. Hong, J. Y. Fang, LncRNA GLCC1 promotes colorectal carcinogenesis and glucose metabolism by stabilizing c-Myc. Nat Commun 10, 3499 (2019).
  8. T. Maj, W. Zou, Rewiring regulatory T cells for tumour killing. Nat Biomed Eng 3, 766-767 (2019).
  9. Liu X, Z. E., Li H, Lesch CA, Dunbar J, Bousley D, Zou W, Hu X, Carter LL. RORγ Agonists Enhance the Sustained Antitumor Activity through Intrinsic Tc17 Cytotoxicity and Tc1 Recruitment. Cancer Immunol Res 7, 1054-1063, doi:10.1158/2326-6066.CIR-18-0714 (2019).
  10. J. Lazarus, Y. Akiska, M. Perusina Lanfranca, L. Delrosario, L. Sun, D. Long, J. Shi, H. Crawford, M. P. Di Magliano, W. Zou, T. Frankel, Optimization, Design and Avoiding Pitfalls in Manual Multiplex Fluorescent Immunohistochemistry. J Vis Exp, (2019).
  11. J. Lazarus, M. D. Oneka, S. Barua, T. Maj, M. P. Lanfranca, L. Delrosario, L. Sun, J. J. Smith, M. I. D'Angelica, J. Shia, J. M. Fang, J. Shi, M. P. Di Magliano, W. Zou, A. Rao, T. L. Frankel, Mathematical Modeling of the Metastatic Colorectal Cancer Microenvironment Defines the Importance of Cytotoxic Lymphocyte Infiltration and Presence of PD-L1 on Antigen Presenting Cells. Ann Surg Oncol 26, 2821-2830 (2019).
  12. X. Lang, M. D. Green, W. Wang, J. Yu, J. E. Choi, L. Jiang, P. Liao, J. Zhou, Q. Zhang, A. Dow, A. L. Saripalli, I. Kryczek, S. Wei, W. Szeliga, L. Vatan, E. M. Stone, G. Georgiou, M. Cieslik, D. R. Wahl, M. A. Morgan, A. M. Chinnaiyan, T. S. Lawrence, W. Zou, Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11. Cancer Discov, (2019).
  13. M. P. Lanfranca, Y. Zhang, A. Girgis, S. Kasselman, J. Lazarus, I. Kryczek, L. Delrosario, A. Rhim, L. Koneva, M. Sartor, L. Sun, C. Halbrook, H. Nathan, J. Shi, H. C. Crawford, M. Pasca di Magliano, W. Zou, T. L. Frankel, Interleukin 22 Signaling 28 Regulates Acinar Cell Plasticity to Promote Pancreatic Tumor Development in Mice. Gastroenterology, (2019).
  14. S. Bishu, M. El Zaatari, A. Hayashi, G. Hou, N. Bowers, J. Kinnucan, B. Manoogian, M. Muza-Moons, M. Zhang, H. Grasberger, C. Bourque, W. Zou, P. D. R. Higgins, J. R. Spence, R. W. Stidham, N. Kamada, J. Y. Kao, CD4+ Tissue-resident Memory T Cells Expand and Are a Major Source of Mucosal Tumour Necrosis Factor alpha in Active Crohn's Disease. J Crohns Colitis 13, 905-915 (2019).
  15. S. Bishu, G. Hou, M. El Zaatari, S. R. Bishu, D. Popke, M. Zhang, H. Grasberger, W. Zou, R. W. Stidham, P. D. R. Higgins, J. R. Spence, N. Kamada, J. Y. Kao, Citrobacter rodentium Induces Tissue-Resident Memory CD4(+) T Cells. Infect Immun 87, (2019).
  16. Wu YM, Cieslik M, Lonigro RJ, et al. Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. Cell 2018;173:1770-1782 e14.
  17. W. Wang, W. Zou, J. R. Liu, Tumor-infiltrating T cells in epithelial ovarian cancer: predictors of prognosis and biological basis of immunotherapy. Gynecol Oncol 151, 1-3 (2018).
  18. J. Lazarus, T. Maj, J. J. Smith, M. Perusina Lanfranca, A. Rao, M. I. D'Angelica, L. Delrosario, A. Girgis, C. Schukow, J. Shia, I. Kryczek, J. Shi, I. Wasserman, H. Crawford, H. Nathan, M. Pasca Di Magliano, W. Zou, T. L. Frankel, Spatial and phenotypic immune profiling of metastatic colon cancer. JCI Insight 3, (2018).
  19. M. P. Lanfranca, J. Lazarus, X. Shao, H. Nathan, M. P. Di Magliano, W. Zou, M. Piert, T. L. Frankel, Tracking Macrophage Infiltration in a Mouse Model of Pancreatic Cancer with the Positron Emission Tomography Tracer [11C]PBR28. J Surg Res 232, 570-577 (2018).

References
  1. "CIMM Steering Committee". AACR.
  2. Curiel, Tyler J.; Coukos, George; Zou, Linhua; Alvarez, Xavier; Cheng, Pui; Mottram, Peter; Evdemon-Hogan, Melina; Conejo-Garcia, Jose R.; Zhang, Lin (September 2004). "Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival". Nature Medicine. 10 (9): 942–949. doi:10.1038/nm1093. ISSN 1078-8956. PMID 15322536.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.